These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19430512)

  • 21. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
    Bendandi M; Gocke CD; Kobrin CB; Benko FA; Sternas LA; Pennington R; Watson TM; Reynolds CW; Gause BL; Duffey PL; Jaffe ES; Creekmore SP; Longo DL; Kwak LW
    Nat Med; 1999 Oct; 5(10):1171-7. PubMed ID: 10502821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA; Timmerman JM
    Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idiotype vaccination for lymphoma: moving towards optimisation.
    Houot R; Levy R
    Leuk Lymphoma; 2009 Jan; 50(1):1-2. PubMed ID: 19172492
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent advances in multiple myeloma immunotherapy.
    Ruffini PA; Biragyn A; Kwak LW
    Biomed Pharmacother; 2002 May; 56(3):129-32. PubMed ID: 12046683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged idiotypic vaccination against follicular lymphoma.
    Inoges S; Lopez-Diaz de Cerio A; Zabalegui N; Soria E; Villanueva H; Panizo C; Rodriguez-Caballero A; Suarez L; Pastor F; Rodriguez-Calvillo M; Orfao A; Bendandi M
    Leuk Lymphoma; 2009 Jan; 50(1):47-53. PubMed ID: 19152172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.
    Lee ST; Jiang YF; Park KU; Woo AF; Neelapu SS
    Expert Opin Biol Ther; 2007 Jan; 7(1):113-22. PubMed ID: 17150023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.
    Navarrete MA; Heining-Mikesch K; Schüler F; Bertinetti-Lapatki C; Ihorst G; Keppler-Hafkemeyer A; Dölken G; Veelken H
    Blood; 2011 Feb; 117(5):1483-91. PubMed ID: 21045197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-specific vaccine therapy for non-Hodgkin lymphoma.
    Hohenstein M; King SE; Fiore JM; O'Brien T; Blumel S
    Clin J Oncol Nurs; 2005 Feb; 9(1):85-90. PubMed ID: 15751502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer vaccine strategies get bigger and better.
    de Gruijl TD; Curiel DT
    Nat Med; 1999 Oct; 5(10):1124-5. PubMed ID: 10502808
    [No Abstract]   [Full Text] [Related]  

  • 30. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM; McGaughey DS; Jaffe ES; Chong EA; Reynolds CW; Berry DA; Santos CF; Popa MA; McCord AM; Kwak LW
    J Clin Oncol; 2011 Jul; 29(20):2787-94. PubMed ID: 21632504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
    Timmerman JM; Vose JM; Czerwinski DK; Weng WK; Ingolia D; Mayo M; Denney DW; Levy R
    Leuk Lymphoma; 2009 Jan; 50(1):37-46. PubMed ID: 19125383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Active immunotherapy in the treatment of haematological neoplasias].
    Inogés S; Rodríguez Calvillo M; López Díaz de Cerio A; Zabalegui N; Melero I; Sánchez Ibarrola A; Rocha E; Bendandi M
    An Sist Sanit Navar; 2004; 27(1):45-62. PubMed ID: 15146205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
    Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Past, present and future of anti-idiotype vaccination].
    Rodríguez Calvillo M; Inogés S; López Díaz de Cerio A; Zabalegui N; Panizo C; Hernández M; Pérez Calvo J; Prósper F; Melero I; Sánchez-Ibarrola A; Rocha E; Bendandi M
    Rev Med Univ Navarra; 2004; 48(3):14-23. PubMed ID: 15622921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.
    Villanueva H; de Cerio AL; Inoges S; Pastor F; Soldevilla MM; Bendandi M
    Expert Rev Vaccines; 2011 Dec; 10(12):1661-9. PubMed ID: 22085168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
    Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
    Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
    J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.
    Muraro E; Martorelli D; Dolcetti R
    Hum Vaccin Immunother; 2013 May; 9(5):1078-83. PubMed ID: 23406835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Active idiotypic vaccination in a patient with biclonal follicular lymphoma.
    Barrios Y; Plaza A; Cabrera R; Yáñez R; Suárez E; Fernández MN; Díaz-Espada F
    Cancer Immunol Immunother; 2001 Apr; 50(2):87-92. PubMed ID: 11401030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development.
    Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Zabalegui N; Villanueva H; Bendandi M
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):1-7. PubMed ID: 15363462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.